Puricase pegloticase: Additional Phase III data

Pooled data from the Phase III GOUT 1 and GOUT 2 trials in 212 patients showed that 8 mg of IV Puricase dosed every 2 or 4 weeks met the secondary endpoint of a significant reduction in the number of ...